SYGNIS announces the adaptation of its organisation to the new business activity
03-Jan-2013
- Germany
These measures are implemented to concentrate the financial resources on the development and marketing of novel technologies in molecular biology in line with the new corporate strategy. This new business was acquired in 2012 by joining forces with the Spanish X-Pol Biotech.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
CPhI Pharma Awards 2015 open with five new categories - Entries now include categories for biopharm, ingredients, supply chain & logistics, manufacturing technology and CEO of the year
Go to page
Algeta initiates new R&D program to investigate a Targeted Thorium Conjugate (TTC) against hematological cancers
Go to page